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Available online 17 November 2011Background: Identification of potentially modifiable risk factors for recurrence in recurrent de-
pression could provide opportunities to improve preventive interventions. In this study we
aimed to examine the predictive value of medically unexplained physical symptoms (MUPS)
on time to recurrence in recurrent depression. Additionally, to elucidate pathophysiological
mechanisms that could explain the relations between MUPS and depression, we investigate
the association between a sustained high level of MUPS, and (I) omega (ω)–3 and −6 fatty
acid (FA)-status and (II) functional polymorphisms in the promoter region of the serotonin
transporter gene (5-HTTLPR).
Methods: Based on three Physical Symptom Checklist (PCS) scores over 12 months, we defined
two groups of remitted recurrently depressed patients: 41 patients with a sustained high num-
ber of MUPS and 34 patients with a sustained low number or no MUPS. Patients were
followed-up for 3.5 years while recurrence of their depression was monitored. In addition,
we analyzed patients' erythrocyte's FA-profiles and triallelically genotyped their 5-HTTLPR.
Results: A sustained high level of MUPS predicted consecutive depression recurrence over
3.5 years (adjusted relative risk 2.8). FA-status and distribution of 5-HTTLPR variant frequen-
cies did not differ between patients with sustained high compared to low/absent MUPS-levels.
Limitations: Our sample was relatively small.
Conclusion: Remitted recurrently depressed patients with sustained MUPS have a considerably
increased risk of recurrence. Having sustained MUPS is not associated with either erythrocyte
ω−3 or−6 FA-levels or 5-HTTLPR polymorphism. Recognition and reducing MUPS in an early
state could prevent a (depressive) relapse.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
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Many patients (40–50%) with depression will have more
than one episode and therefore suffer from the recurrentoundation for Menta
esearch Development
ry, Academic Medica
etherlands. Tel.: +31
ier OA license.l
ltype of this disorder (Mueller et al., 1999; Solomon et al.,
2000). Identifying predictors for recurrence in these patients
is important for a better understanding of the course of this
disease. Well known risk factors for recurrence are: clinical
variables (age at onset of first episode, severity of first episode,
number of previous episodes, residual symptoms), family his-
tory, negative/extreme cognitions, personality (neuroticism),
daily hassles, poor social support and maladaptive coping
styles (Bockting et al., 2006; Burcusa and Iacono, 2007;
Conradi et al., 2008; Fava et al., 2007; ten Doesschate et al.,
2010). These predictors explain only part of the variation in
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risk factors for recurrence in particular could provide an oppor-
tunity for developing targeted preventive intervention.
Somatic symptoms, not attributable to a diagnosable medi-
cal condition, are common in patients with depression
(Demyttenaere et al., 2006; Jain, 2009; Tylee and Gandhi,
2005; Vaccarino et al., 2008). These so-called medically unex-
plained physical symptoms (MUPS) show a wide variety of se-
verity, ranging from a single, mild and transient symptom to a
larger number ofmore chronic and extremely debilitating ones
(Brown, 2007). Insight in the relation between MUPS and de-
pression is interesting because high levels of MUPS in de-
pressed patients may (I) greatly harm their quality of life and
increase the burden of depression (Demyttenaere et al., 2006;
Munoz et al., 2005), (II) hinder full remission (Karp et al.,
2005; Simon et al., 1999; Vieta et al., 2008), and (III) impede
treatment response (Greco et al., 2004; Karp et al., 2005).
Hence, the need for proper recognition of MUPS and apprecia-
tion of their clinical value is unquestionable.
Cross-sectionally, the correlation between depression and
MUPS has been well established (Burton et al., 2011;
Demyttenaere et al., 2006; Munoz et al., 2005; Tylee and
Gandhi, 2005). However, longitudinal studies examining the
temporal relationship between depression and MUPS are
scarce (Bair et al., 2003). It has been postulated that MUPS, in-
stead of fluctuating in severity parallel to the depressive symp-
toms, remain present in between depressive episodes
(Vaccarino et al., 2009). Therefore, MUPS could be regarded as
(I) residual symptoms of a depressive episode, and/or (II) an
early indicator of, or a risk factor for a new depressive episode
(Judd et al., 1998; Vaccarino et al., 2009). Identifying MUPS as
a predictor of recurrence in patients with recurrent depression
could be clinically relevant, also becauseMUPSmay represent a
dynamic modifiable factor involved in recurrence.
The relation between depression and MUPS may be due to
shared underlying biological pathways. In this paper we focus
on two of these related pathways. First, the polyunsaturated
fatty acid (PUFA)-metabolism, because PUFAs (I) participate
in immune regulation (II) determine neuronal membrane sta-
bility, and (III) are involved in neurotransmission and signal
transduction (Assies et al., 2010; Su, 2009). Depression is asso-
ciated with lowered omega-3 (ω−3) fatty acid levels and an
imbalance betweenω−3 and ω−6 PUFAs, which is generally
being hypothesized as harmful (Appleton et al., 2008; Assies
et al., 2010) and might be linked to somatic manifestations
(Su, 2009). Second, another possible underlying mechanism
may be serotonergic pathways, because they are considered
to play a role in both depression and the development of phys-
ical (pain) symptoms (Bair et al., 2003). There is evidence for
an association of longer 5-HTTLPR allele mutations withFig. 1. Time and eveMUPS, while depression itself is associated either with a longer
5-HTTLPR allele mutation or other 5-HTTLPR mutational vari-
ants (Bosker et al., 2010; Hennings et al., 2009; Risch et al.,
2009). Lowered omega-3 FA status is related to serotonergic
disturbances which offer an etiological pathway for mood and
cognitive dysfunction in depression (Su, 2009).
No study thus far has examined the impact of MUPS on the
prognosis of recurrence in the recurrent type of depression.
Therefore, the first aim of our study was to determine the pre-
dictive value of a sustained high level ofMUPS for recurrence in
euthymic patients with recurrent depression. Second, we
aimed to determine whether the biological profiles of the pa-
tients with and without a sustained high level of MUPS differ.
We hypothesized that a high level ofMUPSwould be accompa-
nied by an increasedω−6/ω−3 FA ratio and a higher expres-
sing variant of the 5-HTTLPR polymorphism.
2. Methods
2.1. Study population
The current study was part of the DELTA-study, a random-
ized clinical trial, investigating the effect of cognitive therapy
on recurrence in euthymic patients with ≥2 previous major
depressive episodes (MDEs) in the last 5 years. Among the
exclusion criteria were current or previous mania or hypo-
mania (bipolar disorder), any psychotic disorder (current or
previous), alcohol or drug abuse and predominant anxiety
disorder. Participants were recruited from psychiatric centers
and through media announcement. Recurrence of depression
was the main outcome parameter. Since neither type of after-
care, nor AD use, was an inclusion or exclusion criterion for
the study, with respect to these characteristics, the DELTA
sample can be considered representative for patients suffer-
ing from recurrent depression. All patients provided in-
formed consent to enter the protocol which was approved
by the institutional ethics review committees. The back-
ground and methodology of the DELTA-study is described in
more detail previously (Bockting et al., 2005).
For our MUPS study two periods of the DELTA-study are of
importance (see Fig. 1). The first one, month 12 to month 24
of DELTA, was used to define the MUPS group and includes
three moments of assessment: 12 (T−12), 18 (T−6) and 24
(T0) months after inclusion. The second is the period in
which we assessed recurrence. This follow up starts at
month 24, defined as T0, and runs for 3.5 years.
The DELTA-baseline sample comprised187 participants of
which 15 were excluded because they dropped out of the
study immediately after randomization (Bockting et al.,
2005). From the remaining 172 patients we included thosents schedule.
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and T0, (b) had a valid Physical Symptom Checklist (see
further) at T−12, T−6 and T0, (c) who were euthymic (had
no DSM IV-R diagnosis of major depressive episode) in the
period between T−12 and T0, and (d) had at least one follow
up measurement after T0 (time at risk>0). The latter two cri-
teria were necessary requirements for standard Cox regres-
sion analysis. Of the 187 patients, 78 patients did not fulfill
one or more of the above criteria (24 criterion b, 47 criterion
c, and 7 criterion d), resulting in 109 eligible patients.
2.2. Measures
2.2.1. Medically unexplained symptoms
Physical symptoms were assessed three times (T−12, T−6,
T0) using the Physical Symptom Checklist (PSC) (de Waal et
al., 2004, 2008). The PSC is a self-report checklist comprising
55 physical symptoms covering most organ systems. Four of
these 55 are gender specific (one for men and three for
women). These itemswere excluded to rule out bias by gender.
From the 51 remaining items, 10 items measure autonomous
symptoms, 11 are general/neurological, 8 musculoskeletal/
pain, 13 gastrointestinal, 5 urological/genital items and 4
items are about feeling hot/cold. Each symptom is rated by
the patient on a 4-point Likert scale (0–3) with the preceding
week as the time frame. For the analyses, each symptom
score is dichotomized into ‘not present’ (scores 0 and 1) or ‘pre-
sent’ (i.e. ‘bothersome often ormost of the time during the pre-
viousweek’, scores 2 and 3). The resulting total symptom score
ranges from 0 to 51 and can be considered an indicator of the
severity of somatoform disorders and a predictor of health
care utilization (Kroenke et al., 1994; Speckens et al., 1996).
At the same time as the PCS assessments, patients were
asked in an open interview about their concurrent physical
illnesses. Two clinicians (AS and JA), blind to treatment and
relapse/recurrence, compared the results from the PSC and
the interviews. When a physical illness or complaint men-
tioned by the patient could explain individual items of the
PSC, these items were recoded as ‘not present’. The remaining
items of the PSCwhich could not be explained by a physical ill-
ness were considered ‘medically unexplained physical symp-
toms’. When doubt remained (i.e. 21 physical complaints),
the symptom was regarded as ‘explained’.
2.2.2. Deﬁnition of MUPS groups
Based on the PSC scores at T−12, T−6 and T0 we defined
two patient groups to maximize the contrast: (1) a MUPS+
group comprising 41 patients with a sustained high number
of MUPS (i.e. a PSC score ≥5 at each of the three assess-
ments), and (2) a MUPS− group, comprising 34 patients
with a sustained low number or no MUPS (i.e. a PSC score
b5 at each of the three assessments). This threshold of 5
was based on Escobar's abridged somatization construct SSI
4/6 (de Waal et al., 2008; Escobar et al., 1998). The presence
of high levels of symptoms (e.g. ≥5) was suggested as a rea-
sonable threshold to designate “cases” in clinical and epide-
miological studies. The remaining intermittent group of 34
patients had 5 or more MUPS at some of the 3 assessments
and less than 5 MUPS at the other assessments and was ex-
cluded from the analyses. In summary, both the MUPS+
and MUPS− groups did not suffer from a depressive episodeduring the assessment of the MUPS, and the MUPS that de-
fined that those groups could not be explained by any
known physical condition.
2.2.3. Relapse/recurrence
To assess relapse/recurrence, we used the Structured
Clinical Interview for DSM-IV (SCID-I) (First et al., 1996) at
3.5 years follow-up (T42: the end of the study). At assess-
ment, current and past depressive episodes were checked
by trained SCID evaluators who were blind to treatment con-
dition. Subjects were instructed not to reveal treatment con-
dition to the interviewers (psychologist/research assistants).
All interviews were audio taped. Two independent experi-
enced psychiatrists, blind to treatment condition, evaluated
all occasions of participants meeting the DSM-IV criteria for
MDD. In cases of disagreement, the ratings of the psychia-
trists were used. Kappa for inter-rater agreement between
the interviewers and psychiatrist on categorization of a
relapse/recurrence or no relapse/recurrence was .96, indicat-
ing high agreement.
2.2.4. Sample collection of fatty acids
Fatty acids in washed erythrocytes were analyzed at T0
using capillary gas chromatography, described previously
(Assies et al., 2010). Samples were stored at −80 °C until
analysis.
2.2.5. Genotyping procedures and analysis
For genotyping, two venous blood samples of 10 ml were
taken at T0, mixed with EDTA to prevent coagulation, and
stored at room temperature within 12 h after sampling,
until analysis.
Genomic deoxyribonucleic acid (DNA) was isolated using a
filter-basedmethod (QIAamp DNAMini Kit, Qiagen Ltd, United
Kingdom). The length of the 5-HTTLPR polymorphism was de-
termined by gel electrophoresis. The region around the poly-
morphism was amplified by PCR using forward primer
tgtaaaacgacggccagtgccagcacctaacccctaat and reverse primer
caggaaacagctatgaccaggggagatcctgggaga (M13 primer sequence
in italic). The PCR reaction was performed in 10 μl containing
1.5 mM MgCl2, 0.2 μM forward and reverse primer, 0.1 mM
dNTPs, 0.5 Units Hotfire Polymerase (Solis Biodyne, Estonia),
Buffer B (Solis Biodyne, Estonia) and 20 ng genomic DNA. The
lengths of the four different alleles were: short=250 bp,
long=298 bp, long +=320, long ++=380 bp. Genotyping
of the rs25531 SNP was done by sequencing (Sanger) using
Big Dye Terminators (Applied Biosystems). The M13 forward
primer tgtaaaacgacggccagtwas used for sequencing. 10 μl reac-
tions were performed containing 5 ng of a forward primer, 5 μl
PCR product, BDT mix (Applied Biosystems) and 2.5× BDT
buffer (Applied Biosystems). The length of the 5-HTTLPR poly-
morphism was confirmed by looking at the length of the se-
quenced PCR product.
2.3. Statistical analysis
Analyses were performed in SPSS statistics 18.0 (SPSS,
Inc., 2009, Chicago, IL). The effect of MUPS on recurrence
was assessed with Cox regression, which takes into account
differences in time at risk and censoring (no recurrence
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stricted the analyses to the MUPS+ and MUPS− patient
groups.
Half of the study sample randomly received 8 sessions of
cognitive therapy during the first three months after inclu-
sion in the DELTA study. This therapy prevented recurrence
and its preventive effect increased with the number of previ-
ous depressive episodes (Bockting et al., 2005). To test
whether this intervention modified the relation between
MUPS and recurrence we assessed the significance of the 3-
way interaction of treatment condition by high MUPS by
number of previous episodes' interaction. Because neither
the 3-way MUPS by treatment by previous episodes nor the
2-way MUPS by treatment interaction terms were significant,
both experimental and control groups were pooled for the
Cox-regression analyses. Log–log survival plots showed that
the proportional hazard assumption was met.
To examine whether initial differences in relevant vari-
ables confounded the effect of sustained MUPS, estimates
were adjusted for the potential confounding effects of the fol-
lowing variables by incorporating them as covariates in the
Cox regression analyses: gender, marital status, previous
depressive episodes, early onset of depression (in years), an-
tidepressant use (yes/no, continuous yes/no; monitored with
the Trimbos/IMTA Self Report Questionnaire for Costs Associ-
ated With Psychiatric Illness [TIC-P] and assessed informa-
tion on AD (type and dosage) every 3 months during
follow-up), life events (Negative Life Events Questionnaire),
Personality Disorder Questionnaire total score (PDQ-4+)
and the 90 item Symptom Check List total score (SCL-90)
(Derogatis et al., 1973; Hakkaart-van Roijen et al., 2002;
Hyler, 1994; Kraaij and De Wilde, 2001).
The triallelic genotypes were reclassified into a biallelic
model by their levels of expression. We grouped the geno-
types as S′/S′ (S/S, LG/S, LG/LG), S′/LA (S/LA, LG/LA) and LA/LA.
In the analyses we combined S′/S′ and S′/LA genotypes to
compare them with the high-expressing LA/LA genotype
(Parsey et al., 2006).
Fisher's exact test was used to examine the significance of
the association (contingency) between the two kinds of
MUPS classification regarding the biallelic model. Indepen-
dent means t-tests were performed to detect differences in
FA concentrations between patients with and without sus-
tained high levels of MUPS.
3. Results
The 75 patients (of the 172) comprising the MUPS groups
were comparable to the other 97 patients on gender, educa-
tional level, marital status, % Caucasian, AD use, number of
previous episodes, and age at onset of first depression, but
differed on current age. The MUPS group was on average
3 years older (MUPS groups patients mean age 46.4, sd 8.2;
other patients' mean age 43.4, sd 10.2; t=2.14 df=170,
p=.033).
Characteristics of both MUPS groups are summarized in
Table 1, which shows that both groups were comparable on
the variables tested (all p's>.10), except there were more
women in the MUPS+ group.
Over the consecutive 3.5 year follow-up period (month 24
[T0] to month 66 [T42] of the original trial) time to recurrencewas significantly longer for patients belonging to the MUPS−
group (Fig. 2). In other words, euthymic patients without sus-
tained MUPS stayed significantly longer in remission than pa-
tients who suffered from MUPS, a result which holds, both
with and without correction for potential confounders. Com-
pared to the MUPS− group, the MUPS+ group had a raw rel-
ative risk of 2.6 (Wald(1)=9,38, p=.002) and an adjusted
relative risk of 2.8 to experience a recurrence.
Physical complaints most frequentlymentioned by patients
in the MUPS+ group were: pain in the extremities (54% of
patients), muscle tension (54%), back pain (51%), shortness of
breath, (49%), nausea, (41%) and headaches (37%).
There were no significant differences in total ω−3 and
ω−6 PUFAs and total fatty acids between the MUPS+ and
MUPS− group (Table 2). The concentrations of C20:4ω−6
(arachidonic acid; AA), C20:5ω−3 (eicosapentaenoic acid;
EPA), total ω−6/ω−3, AA/EPA and C20:4ω−6/C22:6ω−3
(AA/DHA) ratioswere comparable betweenbothMUPS groups.
Genotype distribution was in Hardy–Weinberg equilibri-
um in the triallelic (χ2 (3)=4.33, p=.44) but not in the
biallelic (χ2 (1)=4.20, p=.04) model. However, when we
stratified the biallelic model into MUPS+ [(χ2(1)=3.55),
p=.06] and MUPS− [χ2 (1)=1.02, p=.31] groups geno-
type distribution was in Hardy–Weinberg equilibrium in
each stratum. Analyses of serotonin transporter gene promo-
tor polymorphisms in recurrently depressed patients with
high and low levels of MUPS showed that the 20.0% of the
MUPS+ patients and 30.8% of the MUPS− patients had a LA
containing bi-allelic functional profile (L′L′ or L′S′). These dif-
ferences did not reach statistical significance (χ2 (1)=.933,
p=.334). The groups also did not differ with respect to the
triallellic profile (Fisher exact test p=.831).
4. Discussion
The aim of this study was, first, to determine whether re-
mitted recurrently depressed patients with medically unex-
plained physical symptoms (MUPS) have a poor prognosis
over a follow up period of 3.5 years, in terms of recurrence of
depression. During the follow up period 50% of MUPS− pa-
tients and 80% of the MUPS+ patients experienced a new de-
pressive episode. This suggests that a sustained high number
of these symptoms over a 12 month period are predictive for
subsequent recurrence. This result holds when we adjusted
for confounders such as sex and the use of antidepressants,
but alsowhenwe control forwell known illness related predic-
tors for recurrence, i.e. the number of previous episodes, the
age of onset of depression and residual symptoms.
The way we defined and assessed MUPS was meant to as-
certain as well as possible that these somatic symptoms were
not explained by any physical disorder or illness known to
the patient. The predictive power of MUPS could also not be
explained by residual depressive symptoms as we corrected
our analyses for these symptoms. MUPS were also not part
of a depressive episode, because patients were free of such
episodes when MUPS were assessed. Finally, it is unlikely
that the predictive value of MUPS is confounded by antide-
pressant use, because we corrected our analysis for the use
of this medication. One might argue that the reported muscu-
lar tension and shortness of breath, may in fact reflect a high
level of anxiety. However, the association between MUPS and
1,0
0,8
0,6
0,4
0,2
0,0
24 66
MUPS- MUPS+
Months of follow up
Proportion 
free of 
recurrence
Fig. 2. Recurrence of new depressive episodes in patients with low and high
levels of medically unexplained physical symptoms (MUPS).
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logical complaints, including anxiety symptoms. Moreover
patients with premorbid anxiety disorders and substance re-
lated disorders were excluded in this study. So, the reported
MUPS correspond to symptoms that are possibly not related
to these often co-morbid disorders.
Somatic complaints represent a risk factor for the subse-
quent development of depressive symptoms in nonclinical
populations (Escobar et al., 2010; Nakao and Yano, 2006;
Terre et al., 2003). In clinical populations of depressed pa-
tients, physical symptoms, such as pain, are well documented
and common (Perugi et al., 2011; Smith, 1992), and may be
of greater importance to patients than the mood disturbance
(Goldstein et al., 2004). About half of the patients in general
practice with depression suffer from a somatoform disorder
as well (Perugi et al., 2011). This relationship could be due to
anxiety and depression causing (awareness of) physical symp-
toms, or physical symptoms causing anxiety and depression.
Alternatively, this relationship could be explained by a more
complex circular relationship (de Waal et al., 2004), and/or
the existence of common (genetic) risk factors.
MUPS might theoretically develop into a new depressive
episode by two collateral causal pathways. First, simply as an
ongoing common pathophysiological process without any in-
tervening components. Second, in our opinion clinically more
plausible, by a set of mediating factors. Symptoms of e.g. pain,
muscle tension and headachemay interferewith access to pos-
itive reinforcers (i.e. enjoyable activities), lead to increased
feelings of helplessness, and activate negative cognitive
schemas or distortions (e.g. catastrophizing) that contribute
to depression (Campbell et al., 2003; Vaccarino et al., 2009). Ac-
tivated depressive cognitions may contribute to a further mis-
interpretation of physical sensations as being indicative of an
underlying illness (Miranda et al., 2002; Lee et al., 2009).
Alternatively, MUPS and depression can be considered as
two distinct disorders with a common pathogenetic basis.
This basis could be related to the ubiquitously held ‘mono-
amine theory’ of depression which holds that depression is
related to alterations in key neurotransmitters, including se-
rotonin, dopamine and noradrenalin (Hirschfeld, 2000).
These neurotransmitters are also involved in pain modula-Table 2
Erythrocyte fatty acid concentrations (pmol/10e6 erythrocytes) of recur-
rently depressed patients with high and low levels of medically unexplained
physical symptoms (MUPS).
MUPS+ group MUPS− group p
value
(n=31) (n=20)
Eicosapentaenoic
acid (C20:5 ω−3)
3.3±1.1 3.2±1.2 .887
Docosahexaenoic
acid (C22:6 ω−3)
14.8±3.6 14.8±3.8 .992
Arachidonic acid
(C20:4 ω−6)
70.4±7.4 70.9±8.4 .841
C20:4 ω−6/C20:5
ω−3 (AA/EPA)
24.3±8.6 25.6±11.3 .659
C20:4 ω−6/C22:6
ω−3 (AA/DHA)
5.0±1.1 5.0±1.2 .984
Total ω−6/ω−3 6.1±1.2 6.1±1.2 .940
Total fatty acids 588±51 579±59 .619
Independent means t tests.
Table 1
Characteristics of recurrently depressed patients with high and low levels o
medically unexplained physical symptoms (MUPS) at baseline.
Characteristics Total MUPS+
group
MUPS−
group
p
value
(n=75) (n=41) (n=34)
Female (%) 73 85 59 .009
Age (yr, mean,
(SD))
46.4 (8.2) 46.8 (9.0) 45.9(7.3) .638
White (%) 98.7 100 97 .325
Single (%) 40 44 35 .456
BMI (kg/m2)
(mean (SD))
26.6 (4.2) 26.4 (4.5) 26.9 (3.7) .652
Antidepressant
medication (%)
59 63 45 .127
Age of first onset
(yr, mean (SD))
30.3 (12.7) 29.7 (14.3) 31.0 (10.6) .643
Previous episodes
(median (SD))
5.9 (8.6) 7.1 (11.1) 4.4 (3.4) .145
All percentages χ2 test and all continuous variables t tests.ftion, which under normal conditions functions of and to
block or dampen pain signals. Consequently, any ‘alterations’
in these key neurotransmitters would be expected to affect
both pain and depression, and this biological link may help
explain the high rates of comorbidity between pain and de-
pression (Bair et al., 2003; Vaccarino et al., 2009).
In the present study, pain in the extremities and muscle
tension were the most reported (pain related) symptoms; a
finding that is consistent with previous studies frequently
reporting muscle soreness in major depressive disorder
(Campbell et al., 2003; Fornaro et al., 2011; Kluge et al., 2005;
Vaccarino et al., 2009). This symptom might be expected to
contribute to the development of, or vulnerability to, other
(pain-related) symptoms, including those measured in this
study. Although these pain symptoms were accessed as sepa-
rate categories, they may in fact be mediated by the same un-
derlying factor (Vaccarino et al., 2009). In that case
depression and MUPS share common pathways of symptom
development. Interestingly, recent developments postulate
that depression might be related to mitochondrial dysfunction
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might be present in depressed patients with very high levels
of somatic symptoms (Gardner and Boles, 2008).
Somatic symptoms are also thought to be related to higher
expressing alleles (L) of 5-HTTLPR, which should facilitate
higher reuptake rates of serotonin (Hennings et al., 2009;
Narita et al., 2003). However, also links to lower-expressing
allele (S) were reported for fibromyalgia (Offenbaecher et al.,
1999) and for painful symptoms in major depressive disorder
(Smits et al., 2006). We did not find the expected positive asso-
ciation between allelic variation in 5-HTTLPR and a sustained
high level of MUPS in patients with recurrent depression.
MUPS+ patients with recurrent depression did not differ from
MUPS− patients in the frequency of the functional biallelic
form of 5-HTTLPR polymorphism. Unfortunately, we examined
only a single candidate gene. In regard to the heterogeneity of
symptoms in both MUPS and recurrent depression, interactions
of multiple genes as biological bases for the psychiatric pheno-
types are thought to be more likely. Other explanations for our
findings could be that we (I) defined our MUPS groups in
terms of longitudinal, repeated symptomatology, whereas
other studies used other definitions, and (II) were able to
make an absolute contrast with a symptom-free MUPS group.
However, the nature of the connection between 5-HTTLPR alle-
lic variants and somatic symptoms remains to be clarified.
Depression is associatedwith loweredω−3 fatty acid levels
and an imbalance betweenω−3 andω−6 PUFAs. In a previous
study (Assies et al., 2010)we showed that in erythrocytes of pa-
tients with recurrent depression the concentrations of docosa-
hexaenoic acid and arachidonic acid were lower than in
healthy controls, and in addition, patients had a higher ω−3
and ω−6 ratio. In this study, MUPS+ patients with recurrent
depression did not differ from MUPS− patients in their ω−3
and ω−6 PUFA status and the ratios (ω−6/ω−3 AA/EPA,
AA/DHA). Riemer et al. (2010) studied the fatty acid status in
major depressive patients and patients with comorbid somato-
form and depressive disorders. MDD patients and patients
with both disorders had significant higher AA/EPA, AA/DHA
and total w3/w6 in serum cholesterylesters. However, as in
our study, no significant differences for the fatty acid composi-
tion of serum phospholipids were detected. We refrain from
drawing firm conclusions as factors influencing fatty acid me-
tabolism such as dietary intake of fat and fatty acids, the use of
supplements, alcohol consumption, smoking habits and physi-
cal activity were not assessed systematically.
Another limitation is the difficulty to distinguish between
MUPS and physical symptoms that are part of a broader psy-
chiatric condition, such as depression. Although the selection
of appropriate patients for research on MUPS is essential, this
judgment may be difficult to make in clinical practice, partic-
ularly as the co-morbidity between medically unexplained
symptoms, depression and anxiety is extremely high (Smith
et al., 2005). Some researchers have tackled this by assuming
that a physical symptom cannot be regarded as medically
unexplained if it is one of the diagnostic features of major de-
pression or panic disorder (e.g. fatigue, autonomic symptoms
etc.) and full diagnostic criteria for that condition are also
met (Kroenke, 2003). This is potentially problematic as
some physical symptoms can be misdiagnosed as medically
unexplained despite only being present during episodes of
panic or depression that are not severe enough to meetformal criteria for these disorders. Conversely, patients
often experience physical symptoms of this sort and develop
a depressive disorder some time later; many of these patients
are understandably reluctant to view their initial physical
problems as symptoms of a ‘hidden’, ‘masked’ or ‘denied’ psy-
chiatric illness. In a multicenter, international epidemiologic
study, 69% of the patients who met the criteria for depression
reported physical symptoms as their only reason for consult-
ing a physician (Simon et al., 1999). However we tried to
carefully define participants in terms of the presence of re-
currence of depression by undertaking a detailed structured
interview and to exclude those with a current relapse from
our analyses. Post-hoc, we tested whether the predictive
value of MUPS was caused by the fact that some MUPS can be
part of depressive symptomatology, and 8 symptoms were re-
moved from the PCS that are (part of the) criteria of depression
(DSM-IV), namely; items1 (feeling tired or having lowenergy),
2 (easily fatiguedwithout exertion), 8 (sleeplessness), 9 (sleep-
ing a lot), 10 (forgetfulness), 28 (loss of appetite), 29 (weight
loss, last month) and 51 (sexual indifference). This did not
affect the results.
Considering the various views on MUPS in relation to de-
pression, there are several approaches to and opportunities of
integration of different treatments (Fava and Sonino, 2010;
Katsamanis et al., 2011). In our study, MUPS were identified
as dynamic (potentially modifiable) risk factors for recurrence
and could provide the opportunity to preventive intervention.
It is mandatory that the somatic symptoms are recognized
and reduced in an early state to prevent a (depressive) relapse.
In addition, reduction of (pain) symptoms, could establish a
better activity level of patients, and might thereby lower the
risk of recurrence. Primary treatment of MUPS is also relevant
to antidepressant treatment selection, because themechanisms
that may subserve their efficacy for treatment of MUPS are hy-
pothesized to be related to themodulation of both serotonergic
and norepinephrinergic neurotransmission. Thus far, for anti-
depressant treatment of MUPS, there is no clear evidence on
the optimum dose, duration of treatment, or long-term out-
come. In addition, there exists no firm evidence which antide-
pressants or other pharmaceutical agent can be regarded as
the optimal approach to treatMUPS (Sumathipala, 2007). How-
ever, studies suggest that CBT is a promising treatment for
MUPS (Jackson et al., 2006; Kroenke, 2007).5. Conclusion
Sustained medically unexplained physical symptoms pre-
dict relapse and recurrence in recurrent depression. This effect
seems not to be attributable to shared underlying pathological
abnormalities in omega-3 or -6 FA-levels or 5-HTTLPR muta-
tions. More attention for MUPS in patients with recurrent
depression could lead to improved (preventive) treatment
strategies and outcome measures.Role of funding source
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